Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, October 17, 2017

The cardiovascular risk of antidepressant drugs: New data

What is your doctors' analysis of harm vs. benefits post-stroke?

Common antidepressant can help stroke patients improve movement and coordination Sept. 2015 

 

Antidepressants may help people recover from stroke even if they are not depressed Jan. 2013


The cardiovascular risk of antidepressant drugs: New data

In the current issue of Psychotherapy and Psychosomatics a meta-analysis is performed on the cardiovascular risk of antidepressant drugs.Antidepressants are commonly prescribed medications, but their long-term health effects are debated. Antidepressants disrupt multiple adaptive processes regulated by evolutionarily ancient biochemicals, potentially increasing mortality. However, many antidepressants also have anticlotting properties that can be efficacious in treating cardiovascular disease.
Authors conducted a meta-analysis assessing the effects of antidepressants on all-cause mortality and cardiovascular events in general-population and cardiovascular-patient samples. Two reviewers independently assessed articles from PubMed, EMBASE, and Google Scholar for antidepressant-related mortality controlling for depression and other comorbidities. From these articles, information was extracted about cardiovascular events, cardiovascular risk status, and antidepressants class. Authors conducted mixed-effect meta-analyses testing sample type and antidepressants class as moderators of all-cause mortality and new cardiovascular events. Seventeen studies met the search criteria.
Results showed that in the general-population, antidepressants use increased the risks of mortality and new cardiovascular events. In cardiovascular patients, antidepressants use did not significantly affect risks. Antidepressants class also moderated mortality, but the serotonin reuptake inhibitors were not significantly different from tricyclic antidepressants. Only “other antidepressants” were differentiable from tricyclic antidepressants. Mortality risk estimates increased when we analyzed the subset of studies controlling for premedication depression, suggesting the absence of confounding by indication.
Authors concluded that the results support the hypothesis that antidepressants are harmful in the general population but less harmful in cardiovascular patients.
https://www.karger.com/Article/FullText/477940

No comments:

Post a Comment